Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing


Select Volume and Issue


30,00 € / $42.00 / £23.00

Get Access to Full Text

Anti DNA antibodies are not restricted to a specific pattern of fluorescence on HEp2 cells

Geneviève Servais1 / Rafik Karmali2 / Marie Paule Guillaume2 / Valérie Badot2 / Jean Duchateau1 / Francis Corazza1

1Department of Immunology, CHU Brugmann Hospital (Université Libre de Bruxelles), Brussels, Belgium

2Internal Medicine, CHU Brugmann Hospital (Université Libre de Bruxelles), Brussels, Belgium

Corresponding author: Geneviève Servais, Immunology, CHU Brugmann Université Libre de Bruxelles, Place VanGehuchten 4, 1020 Brussels, Belgium Phone: +32 2 477 25 07, Fax: +32 2 477 21 66,

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 47, Issue 5, Pages 543–549, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2009.122, March 2009

Publication History

Published Online:


Background: Antinuclear autoantibody determination relies on an initial screening step using immunofluorescence on HEp2 cells. This may be followed by anti-deoxyribonucleic acid (DNA) determination, if the fluorescence of nuclei is homogeneous. We assessed the validity of a restricted algorithm and compared this to a more comprehensive algorithm that accepted any nuclear pattern as a positive indicator.

Methods: Our retrospective study analyzed routine results for antinuclear antibodies (ANA) and their anti-DNA identification [double stranded nuclear DNA (ds-DNA), membrane associated DNA (mDNA), nucleosomes] for 58 systemic lupus erythematosus (SLE) patients (690 sera). We included 158 patients with systemic or organ-specific autoimmune diseases (888 sera), 44 with viral disease (88 sera), 34 cancer patients (89 sera) and 111 patients with inflammation that served as controls (122 sera) for a total of 1187 samples.

Results: 1) Anti DNA antibodies are not associated only with a homogeneous pattern, but can also be seen with a speckled or nucleolar pattern. 2) The observed pattern is typical for a particular patient rather than for a specific pathology. 3) A homogeneous pattern does not necessarily indicate SLE, nor does the presence of circulating anti DNA antibodies. 4) Determination of various specificities of anti DNA antibodies, whatever the immunofluorescent pattern, increases the sensitivity and specificity for SLE.

Conclusions: If diagnosis is based exclusively on a homogenous pattern, preselection would have missed identification of SLE as high levels of anti DNA antibodies were also associated with speckled or nucleolar pattern.

Clin Chem Lab Med 2009;47:543–9.

Keywords: anti DNA; antinuclear antibodies; auto-antibodies; HEp2; SLE

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Renata Baronaite, Merete Engelhart, Troels Mørk Hansen, Gorm Thamsborg, Hanne Slott Jensen, Steen Stender, and Pal Bela Szecsi
Autoimmune Diseases, 2014, Volume 2014, Page 1
N. Agmon-Levin, J. Damoiseaux, C. Kallenberg, U. Sack, T. Witte, M. Herold, X. Bossuyt, L. Musset, R. Cervera, A. Plaza-Lopez, C. Dias, M. J. Sousa, A. Radice, C. Eriksson, O. Hultgren, M. Viander, M. Khamashta, S. Regenass, L. E. C. Andrade, A. Wiik, A. Tincani, J. Ronnelid, D. B. Bloch, M. J. Fritzler, E. K. L. Chan, I. Garcia-De La Torre, K. N. Konstantinov, R. Lahita, M. Wilson, O. Vainio, N. Fabien, R. A. Sinico, P. Meroni, Y. Shoenfeld, J. C. Tervaert, D. Hamann, R. Derksen, H. Hooijkaas, I. Klasen, P. Limburg, R. Smeenk, P. van Daele, K. Elvin, C. Dahle, T. Skogh, J. Antonen, A.-M. Haapala, M. Hietarinta, T. Hakkinen, A. Hanninen, S. Jokiranta, A. Karjalainen, A. Laatikainen, M. Leirisalo-Repo, R. Luosujarvi, A. Miettinen, J. Siuro, S. Sved, T. Tuuminen, T. Walle, F. Coelho, M. J. Santos, M. Bogas, J. P. Ramos, J. Faro-Viana, N. O. Olsson, G. Chyderiotis, Bach-Nga, V. Aubert, C. Dahinden, E. Dayer, F. Mascart, J.-P. Tomasi, M. Vercammen, P. Verschueren, F. Houssiau, B. Lauwerys, F. De Keyser, W. Fierz, I. Heijnen, F. Keller, G. Mullner, S. Regenass, P. Roux-Lombard, U. Wirthmuller, B. Gilburde, R. Levi, D. Lipinsky, M. Barak, A.-S. Mahmud, R. Fishel, M. Foguel, K. Shay, E. Csernok, B. Schluter, B. Becker, R. Mierau, T. Witte, W. Seidel, I. Frank, A. Kromminga, F. Hiepe, K. Conrad, M. Sticherling, G. Steiner, C. Valentyna, I. Alcala, M. Alsina, A. M. Jose, A. Carrasco, L. Fernandez, M. A. Figueredo, C. Gelpi, J. Jimenez, M. R. Julia, M. Lopez-Hoyos, L. Mozo, C. Munoz, F. J. Munoz, P. Palomino, A. Prada, C. R. Hernandez, G. Roy, E. Ruiz, and L. Vargas
Annals of the Rheumatic Diseases, 2014, Volume 73, Number 1, Page 17
Wendy Y. Craig and Thomas B. Ledue
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 7

Comments (0)

Please log in or register to comment.